Quarterly ResultApr 30, 2026, 06:02 PM
YDES FY25 Net Revenue +17% to $597K; Net Loss $8.3M; Strategic Growth
AI Summary
YD Bio reported full-year 2025 net revenue of $597K, a 17% increase, driven by expanded pharmaceutical sales and new product launches. The company posted a net loss of $8.3 million, significantly higher than the previous year, primarily due to increased operating expenses, including R&D and professional fees related to expansion. YD Bio strengthened its balance sheet with a business combination and a $13.2 million PIPE financing, ending the year with $6.0 million in cash. Strategic initiatives for 2026 include advancing its Limbal Stem Cell platform and OkaiDx™ Pancreatic Cancer Early Detection Program towards FDA submissions, and pursuing M&A, including a merger with EG BioMed.
Key Highlights
- Completed business combination with Breeze Holdings and $13.2M PIPE financing in August 2025.
- Net Revenue increased 17% to $597K for FY2025, up from $510K in FY2024.
- Net Loss was $8.3M for FY2025, compared to $1.4M in FY2024.
- Cash and cash equivalents were $6.0M as of December 31, 2025, up from $3.1M.
- R&D expenses increased by $1.1M; total operating expenses rose to $5.4M.
- Filed Drug Master Files with FDA for Limbal Stem Cell platform and derived exosome products.
- Advancing OkaiDx™ Pancreatic Cancer Early Detection Program for FDA Q-Submission.
- Announced MoU to merge with EG BioMed and LoI to acquire Safe Save Medical Cell Sciences.